Old photos of 'Love Island' contestant Melanie Moreno modeling for Pretty Little Thing during Miami Swim Week, which occurred in 2022, sparked a firestorm. Accusations of Ozempic use quickly followed her noticeable weight loss. This public reaction ignited an intense debate in 2026 about former plus-size models and body image, with the resurfacing images drawing significant scrutiny, according to PopRant.
Moreno's family insists she achieved her current body through hard work. Yet, widespread social media speculation suggests she used weight loss drugs like Ozempic. Video footage of Moreno as a plus-size model circulating online further fueled this speculation, as reported by WWD.
The intense public focus on Moreno's transformation exposes persistent societal pressure on women's appearances and the rapid spread of unsubstantiated claims online. Her sudden re-emergence into public debate highlights the intense scrutiny public figures face over their bodies.
Why is Melanie Moreno's weight loss a public concern?
Videos and photos of Moreno modeling for Pretty Little Thing during Miami Swim Week 2022 fueled immediate speculation about her weight loss. Social media users quickly suggested Ozempic use, according to The Daily Beast. This rapid spread of unverified claims, despite family denials, reveals a public narrative shift: for figures like Moreno, weight loss is now often attributed to pharmaceutical shortcuts rather than personal effort. This erodes trust and personal ownership over one's body story.
How did Melanie Moreno's family respond to Ozempic rumors?
Melanie Moreno's family vehemently denied Ozempic accusations. Her cousin stated Moreno worked hard for her current body and was never insecure about her size, according to Reality Blurb. This forceful denial attempts to reframe the narrative as one of personal effort and body positivity. However, it also reveals a public reluctance to accept natural explanations for significant weight loss in public figures when a pharmaceutical shortcut is readily perceived.
